Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
quadrivalent split-virion inactivated influenza vaccine
- Development stage
- Unknown
- Lead developer
- Sanofi
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The quadrivalent split-virion inactivated influenza vaccine is a seasonal vaccine designed to protect against four different influenza virus strains: two influenza A subtypes (H1N1 and H3N2) and two influenza B lineages (Victoria and Yamagata). The "split-virion" technology involves disrupting the viral envelope with detergents, which releases the essential surface antigens while reducing the risk of systemic adverse reactions compared to whole-virus vaccines. By including both B lineages, the quadrivalent formulation provides broader coverage than traditional trivalent vaccines. Major developers include Sanofi Pasteur, GSK, and Chinese manufacturers such as Sinovac Biotech and Zhifei Longcom. The vaccine is typically administered via intramuscular injection and is updated annually to match circulating strains as recommended by the World Health Organization.
- Brand names
- VaxigripTetraFluarix TetraFluQuadriAfluria QuadrivalentAnflu
- Other names
- QIVQIV-Squadrivalent influenza vaccine (split virion, inactivated)influenza vaccine (split virion, inactivated, quadrivalent)
02
Targets
HA (Hemagglutinin)Neuraminidase
Beyond the preview
Go deeper on quadrivalent split-virion inactivated influenza vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on quadrivalent split-virion inactivated influenza vaccine.